Unbound MEDLINE

L-Carnosine: multifunctional dipeptide buffer for sustained-duration topical ophthalmic formulations. The Journal of pharmacy and pharmacology [J Pharm Pharmacol] Journal article

 
TitleL-Carnosine: multifunctional dipeptide buffer for sustained-duration topical ophthalmic formulations.
Author(s)Singh SR, Carreiro ST, Chu J, Prasanna G, Niesman MR, Collette Iii WW, Younis HS, Sartnurak S, Gukasyan HJ 
InstitutionDepartment of Pharmaceutical Sciences, University of Nebraska Medical Center, Omaha, Nebraska, USA.
SourceJ Pharm Pharmacol 2009 Jun; 61(6):733-42.
AbstractOBJECTIVES: The use of l-carnosine as an excipient in topical ophthalmic formulations containing gellan gum, a carbohydrate polymer with in-situ gelling properties upon mixing with mammalian tear fluid, was developed as a novel platform to extend precorneal duration. Specific utilisation of l-carnosine as a buffer in gellan gum carrying vehicles was characterised.
METHODS: Buffer capacity was evaluated using 7.5, 13.3, and 44.2 mm l-carnosine in a pH range of 5.5-7.5. Accelerated chemical stability was determined by HPLC at l-carnosine concentrations of 5-100 mm. Combinations of 7.5 mm l-carnosine with 0.06-0.6% (w/v) gellan gum were characterised rheologically. l-Carnosine-buffered solutions of gellan gum were tested for acute topical ocular tolerance in vivo in pigmented rabbits. A unique formulation combining timolol (which lowers intraocular pressure) in l-carnosine-buffered gellan gum was compared with Timoptic-XE in normotensive dogs. KEY
FINDINGS: l-Carnosine exhibited optimal pharmaceutical characteristics for use as a buffer in chronically administered topical ocular formulations. Enhancement trends were observed in solution-to-gel transition of l-carnosine-buffered vehicles containing gellan gum vs comparators. Topical tolerability of l-carnosine-buffered gellan gum formulations and lowering of intraocular pressure were equivalent with timolol and Timoptic-XE.
CONCLUSIONS: Functional synergy between excipients in gellan gum formulations buffered with l-carnosine has potential for topical ocular dosage forms with sustained precorneal residence.
Languageeng
Pub Type(s)Journal Article
Research Support, Non-U.S. Gov't
PubMed ID19505363
  
Advertise on this site.